Neuragen PN Product Information

The science behind Neuragen was discovered by Dr. Bruce Frome at the National Pain Institute and has been the subject of several clinical studies. Classed as GRAS by the FDA, Neuragen can be used to reduce discomfort resulting a range of medical conditions.

A print-ready product information sheet is available in PDF format.

History of Development

Dr. Bruce Frome discovered the effectiveness of certain botanical oils in the early 1990’s while managing the National Pain Institute in California, a tertiary care center for patients with chronic disabling pain. The clinic provided treatments of last resort for patients with pain from diabetes, shingles, fibromyalgia, spinal compression, post-surgical and accident induced nerve damage, and other conditions. Many of these patients were willing to serve as subjects in his efforts to discover more effective analgesics for this neuropathic pain.

In the initial studies, Dr. Frome applied 200 essential oils, which are normally used in aromatherapy, to patients suffering from these various neuralgias. They recorded the degree of pain relief over a few hours in his office. Only specific varieties and sources of these oils provided significant pain relief. The pain relief was almost immediate and lasted for several hours. Since that time, thousands of patients have used the medication at a number of large chronic pain clinics in the US and Canada, and this discovery has received a US patent. In August 2005, Neuragen was also registered as an over-the-counter drug by the US Food and Drug Administration.

Safety of Neuragen

The botanical oils and its fractions used in Neuragen have been used in foods and cosmetics for decades. The U.S. Food and Drug Administration considers these oils to be generally regarded as safe (GRAS). The extensive clinical testing, the only detectable side effect is minor skin irritation in a slight minority of patients with sensitive skin. Please discontinue use if this occurs. There have been no reported adverse side effects when used according to directions. A flora aroma is pronounced due to the aromatic nature of the ingredients.

Development of NeuraGEL

NeuraGEL® has been developed in order to address requests for the same Neuragen effectiveness, but formulated as an easy to apply gel.

Neuragen Clinical Studies

Neuragen has been used extensively by health care professionals in the USA and Canada since 1990 for the treatment of chronic pain associated with diabetic neuropathy, shingles, fibromyalgia, post-surgical and accident induced nerve damage and other related conditions. Many patients have been successfully treated who have failed to respond to other common treatments.

Clinical Trials

In 1992, the active ingredient in Neuragen was tested in a multicentre, monitored, placebo-controlled study for safety and efficacy in the treatment of post-herpetic neuralgia (post-shingles pain). This is a chronic neuropathic pain condition caused by an outbreak of shingles (Herpes zoster). The design applied one treatment per day in a single-blinded, randomized, prospective, balanced crossover study of five groups of six patients each (30 patients total). The trial was conducted at two centers: National Pain Institute, CA and Pennington Research Institute, LA. The results are statistically significant, and showed that better than 3 out of 5 patients reported effective pain relief (Figure 1). The active ingredients in Neuragen began relieving pain within 5 to 15 minutes and relief was still increasing at the end of one hour. Side effects were minor and no different than mineral oil. Neuragen is a safe and rapidly effective treatment for the pain of post-herpetic neuralgia.

In 2004, Neuragen was tested in a Sacramento, CA area study for the foot pain caused by diabetes (diabetic peripheral neuropathy), and showed a similar high effectiveness rate. Out of 29 patients, 69% noted some improvement in pain. A remarkable 59% of these patients noting a 50-100% improvement in pain (Figure 2 [PDF file]). Quality of life benefits included improved joint flexibility and balance and decreased cramping, as well as improvement in sleep, work ability and energy. Many patients reported that Neuragen worked better for them than any other medication. Repeated use of Neuragen decreased levels of pain for some patients after only one month of use.

Clinical Use of Neuragen

Neuragen has been used effectively in a clinical setting as the primary prescriptive treatment, or adjunct treatment, by many health care professionals for the following indications:

• Shingles (Herpes zoster)
• Post-Herpetic Neuralgia (Post-shingles pain)
• Diabetic Peripheral Neuropathies (Hand and foot pain)
• Reflex Sympathetic Dystrophies (RSD)
• Fibromyalgia
• Post-surgery or accident induced neuropathy
• Causalgias
• Radiculopathies
• Phantom Limb Pain
• Bell’s Palsy
• Trigeminal Neuralgias
• Mysofascial Pain
• Chemotherapy or HIV Neuropathic Pain
• Sciatica / Spinal Compression

We recommend that you consult your health care professional about combining Neuragen with your current treatment, or as your primary treatment. Ask your health care professional to request the results of these clinical studies.

Further Clinical Studies

Additional trials of Neuragen are being planned. If you would like to consider enrolling in these studies, or would like further information, please contact This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

This information is not intended as medical advice. Its intention is solely educational. Please consult a medical or health professional for medical advice.